Transforming Osteoarthritis Treatment through Federated Big Data and AI-driven Clinical Innovation
PROBE (Patient Relevant Osteoarthritis endpoints using Big data Evaluation) is a large-scale public-private partnership and pioneering initiative that aims to revolutionise the way osteoarthritis (OA) is understood, diagnosed, and treated by developing patient-relevant endpoints, advanced predictive models, and next-generation clinical trial designs using federated big data and AI technologies.
Key Features
Development of novel multimodal endpoints to support better treatment evaluation
Creation of a regulation-compliant federated OA database network
Use of foundation AI models to predict progression and support personalised medicine.
Tools for shared decision-making between patients and healthcare providers
Strong engagement with patients, caregivers, regulators, HTA bodies, and clinicians
Key Numbers
Partners
PROBE unites 38 partners from academia, industry, patient organisations, regulatory bodies, and healthcare professionals across Europe and beyond. The project is jointly led by Erasmus MC Medical University Center and Novartis, embodies a strong public-private commitment to transforming evidence-based OA research and improving patient care and outcomes on a global scale.
